Veliparib-Induced Toxicity in Cancer Patients: A Systematic Review and Meta-Analysis

被引：0

作者：

Wang, Peirong ^{[1
]}

Zhao, Ruizhen ^{[1
]}

Jin, Xiaohui ^{[2
]}

Zhou, Xianhua ^{[1
]}

Xie, Xiaolong ^{[3
]}

机构：

[1] Chinese Tradit Med Hosp Meishan, Internal Med Tradit Chinese Med, Meishan, Peoples R China

[2] Chinese Tradit Med Hosp Meishan, Dept Neurol, Meishan, Peoples R China

[3] Chinese Tradit Med Hosp Meishan, Bone injury Tradit Chinese Med, Meishan, Sichuan, Peoples R China

来源：

CANCER INVESTIGATION | 2024年 / 42卷 / 03期

关键词：

Veliparib; adverse events; cancer; meta-analysis; systematic review; LAPAROSCOPIC RADICAL PROSTATECTOMY; URINARY-INCONTINENCE;

D O I：

10.1080/07357907.2024.2338128

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this study, we investigate the veliparib-induced toxicity in cancer patients. Databases were searched for RCTs treated with veliparib. We found veliparib could increase the risk of hematologic and gastrointestinal toxicities. Anemia, neutropenia, thrombocytopenia, and nausea were the most common toxicities. Patients diagnosed with gastrointestinal tumors tend to have a higher risk of high-grade neutropenia; patients in the first-line setting tend to have a higher risk of high-grade anemia and neutropenia than those in the >= second line setting. Patients receiving higher dosage of veliparib tend to have a higher risk of all-grade anemia. Veliparib could also increase the risk of insomnia, myalgia, pneumonia, dyspnea, hyponatremia, and fatigue.

引用

页码：260 / 273

页数：14

共 34 条

[1] Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors [J].

Aliyuda, Fine ;

Moschetta, Michele ;

Ghose, Aruni ;

Rallis, Kathrine Sofia ;

Sheriff, Matin ;

Sanchez, Elisabet ;

Rassy, Elie ;

Boussios, Stergios .

CURRENT CANCER DRUG TARGETS, 2023, 23 (06) :433-446

[2] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies [J].

Appleman, Leonard J. ;

Beumer, Jan H. ;

Jiang, Yixing ;

Lin, Yan ;

Ding, Fei ;

Puhalla, Shannon ;

Swartz, Leigh ;

Owonikoko, Taofeek K. ;

Harvey, R. Donald ;

Stoller, Ronald ;

Petro, Daniel P. ;

Tawbi, Hussein A. ;

Argiris, Athanassios ;

Strychor, Sandra ;

Pouquet, Marie ;

Kiesel, Brian ;

Chen, Alice P. ;

Gandara, David ;

Belani, Chandra P. ;

Chu, Edward ;

Ramalingam, Suresh S. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) :1289-1301

[3] A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811) [J].

Argiris, Athanassios ;

Miao, Jieling ;

Cristea, Mihaela C. ;

Chen, Allen M. ;

Sands, Jacob M. ;

Decker, Roy H. ;

Gettinger, Scott N. ;

Daly, Megan E. ;

Faller, Bryan A. ;

Albain, Kathy S. ;

Yanagihara, Ronald H. ;

Garland, Linda L. ;

Byers, Lauren A. ;

Wang, Ding ;

Koczywas, Marianna ;

Redman, Mary W. ;

Kelly, Karen ;

Gandara, David R. .

CLINICAL LUNG CANCER, 2021, 22 (04) :313-+

[4] Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach [J].

Boussios, Stergios ;

Karihtala, Peeter ;

Moschetta, Michele ;

Abson, Charlotte ;

Karathanasi, Afroditi ;

Zakynthinakis-Kyriakou, Nikolaos ;

Ryan, Jake Edward ;

Sheriff, Matin ;

Rassy, Elie ;

Pavlidis, Nicholas .

INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) :181-193

[5] Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study [J].

Byers, Lauren Averett ;

Bentsion, Dmitry ;

Gans, Steven ;

Penkov, Konstantin ;

Son, ChoonHee ;

Sibille, Anne ;

Owonikoko, Taofeek K. ;

Groen, Harry J. M. ;

Gay, Carl M. ;

Fujimoto, Junya ;

de Groot, Patricia ;

Dunbar, Martin ;

Kang, Kingston ;

He, Lei ;

Sehgal, Vasudha ;

Glasgow, Jaimee ;

Bach, Bruce Allen ;

Ellis, Peter M. .

CLINICAL CANCER RESEARCH, 2021, 27 (14) :3884-3895

[6] Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis [J].

Cai, Zhaolun ;

Liu, Chunyu ;

Chang, Chen ;

Shen, Chaoyong ;

Yin, Yuan ;

Yin, Xiaonan ;

Jiang, Zhiyuan ;

Zhao, Zhou ;

Mu, Mingchun ;

Cao, Dan ;

Zhang, Lingli ;

Zhang, Bo .

PHARMACOLOGICAL RESEARCH, 2021, 172

[7] Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study [J].

Chabot, Pierre ;

Hsia, Te-Chun ;

Ryu, Jeong-Seon ;

Gorbunova, Vera ;

Belda-Iniesta, Cristobal ;

Ball, David ;

Kio, Ebenezer ;

Mehta, Minesh ;

Papp, Katherine ;

Qin, Qin ;

Qian, Jane ;

Holen, Kyle D. ;

Giranda, Vince ;

Suh, John H. .

JOURNAL OF NEURO-ONCOLOGY, 2017, 131 (01) :105-115

[8] Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 [J].

Chiorean, E. Gabriela ;

Guthrie, Katherine A. ;

Philip, Philip A. ;

Swisher, Elizabeth M. ;

Jalikis, Florencia ;

Pishvaian, Michael J. ;

Berlin, Jordan ;

Noel, Marcus S. ;

Suga, Jennifer M. ;

Garrido-Laguna, Ignacio ;

Cardin, Dana Backlund ;

Radke, Marc R. ;

Duong, Mai ;

Bellasea, Shay ;

Lowy, Andrew M. ;

Hochster, Howard S. .

CLINICAL CANCER RESEARCH, 2021, 27 (23) :6314-6322

[9] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[10] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial [J].

Dieras, Veronique ;

Hanc, Hyo S. ;

Wildiers, Hans ;

Friedlander, Michael ;

Ayoub, Jean- Pierre ;

Puhalla, Shannon L. ;

Loirat, Delphine ;

Ratajczak, Christine ;

Adamu, Hephzibah ;

Girardi, Vincent ;

Arun, Banu K. .

EUROPEAN JOURNAL OF CANCER, 2024, 200

← 1 2 3 4 →